Aclaris Therapeutics ACRS Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Aclaris Therapeutics’s reported figures.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's free cash flow?
- Aclaris Therapeutics (ACRS) reported free cash flow of -$18.16M in Q1 2026.
- How has Aclaris Therapeutics's free cash flow changed year-over-year?
- Aclaris Therapeutics's free cash flow decreased by 38.6% year-over-year, from -$13.1M to -$18.16M.
- What is the long-term trend for Aclaris Therapeutics's free cash flow?
- Over 2 years (2022 to 2025), Aclaris Therapeutics's free cash flow has grown at a -16.8% compound annual growth rate (CAGR), from -$68.17M to -$47.22M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.